Canadian healthcare capacity gaps for disease-modifying treatment in Huntington’s disease: a survey of current practice and modelling of future needs
Objectives Disease-modifying therapies in development for Huntington’s disease (HD) may require specialised administration and additional resource capacity. We sought to understand current and future capacity for HD management in Canada considering the possible introduction of an intrathecal (IT) di...
Saved in:
Main Authors: | Sylvain Chouinard, Blair R Leavitt, Angèle Bénard, Nathalie Budd, Jennifer W Wu, Kerrie Schoffer |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2022-06-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/12/6/e062740.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Pilot Proteomic Analysis of Huntington’s Disease by Functional Capacity
by: Andrew McGarry, et al.
Published: (2025-01-01) -
The Role of the Immune System in Huntington’s Disease
by: Gisa Ellrichmann, et al.
Published: (2013-01-01) -
deutetrabenazine for the treatment of chorea associated with Huntington’s disease
by: Harshit Gupta, et al.
Published: (2022-06-01) -
The Role of Dopamine and Glutamate Modulation in Huntington Disease
by: Sumeer K. Mittal, et al.
Published: (2013-01-01) -
Laser Evoked Potentials in Early and Presymptomatic Huntington’s Disease
by: Marina de Tommaso, et al.
Published: (2016-01-01)